

sequence for the adenoviral vector. Furthermore, the E1 region in this vector has been replaced with a construct, which consists of a bleomycin resistance gene, and an insect N-defensin gene under control of the *E. coli* lac promoter. The nucleic acids encoding the chimeric protein IX mutants, present on a small and easily manipulated cloning vector, are recombined into the E1 region of the doubly ablated adenoviral vector using methods known to those skilled in the art. This also introduces a CMV promoter-driven marker enzyme gene such as luciferase into the E1 region.

IN THE SEQUENCE LISTING:

The Examiner is respectfully requested to substitute the enclosed paper copy of a corrected Sequence Listing for the copy of the Sequence Listing that Applicants filed on May 11, 2001.

REMARKS

In accordance with the requirements of 37 CFR 1.821-1.825, a nucleotide/amino acid sequence listing is being submitted as part of the above-identified patent application. The sequence listing is in the form of both a paper copy and a computer readable copy on a computer diskette. The undersigned agent verifies that the paper copy of the sequence listing and the computer-readable copy of the sequence listing submitted herewith are identical.

Applicants gratefully acknowledge the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 21, 2002. The Notice is directed two amino acid sequences appearing in the application's specification at page 11, paragraph 0029, for which no corresponding sequences appear in the application's paper and electronic sequence listing submission. Applicants therefore have amended the specification to recite sequence identification numbers for the two amino acid sequences, and have amended the application's sequence listing submission to incorporate the two amino acid sequences.


The amendments do not go beyond the disclosure of the application as filed and do not contain any new matter.

In re Appln. of ROELVINK et al.
Application No. 09/780,224

REMARKS

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned agent.

Respectfully submitted,



Heather R. Kissling, Reg. No. 45,790
One of the Agents for Applicant(s)
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: June 27, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including any documents or materials referred to thereon as being enclosed or attached, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, Virginia 22202

June 27, 2002

Peter Panklitz